JP2013520443A5 - - Google Patents

Download PDF

Info

Publication number
JP2013520443A5
JP2013520443A5 JP2012554085A JP2012554085A JP2013520443A5 JP 2013520443 A5 JP2013520443 A5 JP 2013520443A5 JP 2012554085 A JP2012554085 A JP 2012554085A JP 2012554085 A JP2012554085 A JP 2012554085A JP 2013520443 A5 JP2013520443 A5 JP 2013520443A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
ring
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012554085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520443A (ja
JP5805672B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/025661 external-priority patent/WO2011103546A1/en
Publication of JP2013520443A publication Critical patent/JP2013520443A/ja
Publication of JP2013520443A5 publication Critical patent/JP2013520443A5/ja
Application granted granted Critical
Publication of JP5805672B2 publication Critical patent/JP5805672B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012554085A 2010-02-22 2011-02-22 脂肪酸合成酵素阻害剤としてのトリアゾロン類 Expired - Fee Related JP5805672B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30670910P 2010-02-22 2010-02-22
US61/306,709 2010-02-22
US35758710P 2010-06-23 2010-06-23
US61/357,587 2010-06-23
PCT/US2011/025661 WO2011103546A1 (en) 2010-02-22 2011-02-22 Triazolones as fatty acid synthase inhibitors

Publications (3)

Publication Number Publication Date
JP2013520443A JP2013520443A (ja) 2013-06-06
JP2013520443A5 true JP2013520443A5 (OSRAM) 2014-03-13
JP5805672B2 JP5805672B2 (ja) 2015-11-04

Family

ID=44483349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012554085A Expired - Fee Related JP5805672B2 (ja) 2010-02-22 2011-02-22 脂肪酸合成酵素阻害剤としてのトリアゾロン類

Country Status (13)

Country Link
US (2) US8802864B2 (OSRAM)
EP (1) EP2538787B1 (OSRAM)
JP (1) JP5805672B2 (OSRAM)
KR (1) KR20120133386A (OSRAM)
CN (1) CN102858175A (OSRAM)
AU (1) AU2011217809A1 (OSRAM)
BR (1) BR112012020976A2 (OSRAM)
CA (1) CA2790692A1 (OSRAM)
EA (1) EA201290822A1 (OSRAM)
ES (1) ES2509951T3 (OSRAM)
MX (1) MX2012009720A (OSRAM)
SG (1) SG183260A1 (OSRAM)
WO (1) WO2011103546A1 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102858175A (zh) * 2010-02-22 2013-01-02 葛兰素史密斯克莱有限责任公司 作为脂肪酸合成酶抑制剂的三唑酮
WO2013134562A1 (en) * 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
MX376108B (es) 2012-12-20 2025-03-07 Tempest Therapeutics Inc Compuestos de triazolona y usos de los mismos.
ES2651331T3 (es) * 2013-01-10 2018-01-25 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de la sintasa de ácidos grasos
KR102194745B1 (ko) 2013-03-13 2020-12-24 포르마 세라퓨틱스 인크. Fasn 억제용 신규 화합물 및 조성물
CN105899521A (zh) 2013-09-05 2016-08-24 陶氏益农公司 制备硼基化芳烃的方法
KR20160048988A (ko) 2013-09-06 2016-05-04 인셉션 2 인코퍼레이티드 트라이아졸론 화합물 및 이의 용도
EP3083600B1 (en) 2013-12-17 2018-09-26 Janssen Pharmaceutica NV Imidazolin-5-one derivatives useful as fasn inhibitors for the treatment of cancer
TW201625354A (zh) 2014-06-16 2016-07-16 陶氏農業科學公司 用於製備氧硼基化芳烴之方法
CN104876917B (zh) * 2015-06-16 2017-09-19 上海皓元医药股份有限公司 用作脂肪酸合成酶抑制剂的三唑酮的合成方法
MX379846B (es) 2015-06-18 2025-03-11 89Bio Ltd Derivados de 4-bencil y 4-benzoil piperidina sustituidos.
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114539193B (zh) * 2022-01-20 2024-08-06 安徽普利药业有限公司 一种盐酸胺碘酮中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728834A (en) * 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
EP1615878B1 (en) * 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
CA2577937C (en) * 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007056170A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US8236792B2 (en) * 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
CN102858175A (zh) * 2010-02-22 2013-01-02 葛兰素史密斯克莱有限责任公司 作为脂肪酸合成酶抑制剂的三唑酮

Similar Documents

Publication Publication Date Title
JP2013520443A5 (OSRAM)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
Yu et al. Natural product-derived spirooxindole fragments serve as privileged substructures for discovery of new anticancer agents
JP2013507425A5 (OSRAM)
RU2016130932A (ru) Производные хинолона как ингибиторы рецептора фактора роста фибробластов
RU2012138709A (ru) Производные арилметокси изоиндолина и композиции, включающие их, и способы их применения
JP2013510120A5 (OSRAM)
JP2014503567A5 (OSRAM)
JP2013510178A5 (OSRAM)
JP2009263394A5 (OSRAM)
JP2013510124A5 (OSRAM)
JP2018516238A5 (OSRAM)
JP2013544261A5 (OSRAM)
JP2018525375A5 (OSRAM)
JP2016530283A5 (OSRAM)
ME02838B (me) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
JP2014534269A5 (OSRAM)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2010513523A5 (OSRAM)
JP2017502940A5 (OSRAM)
RU2017114687A (ru) Ингибитор egfr и его получение и применение
RU2016137181A (ru) Противофиброзные пиридиноны
JP2016523974A5 (OSRAM)
JP2016525076A5 (OSRAM)